NeuroVive starts preclinical TBI program in collaboration with PENN

NeuroVive Pharmaceutical AB (publ), the pioneers in mitochondrial medicine,
announces the start of the first study in the preclinical program in traumatic
brain injury (TBI) which is being done in collaboration with the University of
Pennsylvania (PENN).
The TBI preclinical research program includes 3 different studies evaluating the
protective effect of NeuroSTAT® in a TBI experimental model. TBI is an important
unsolved problem in the medical field: nerve cell protection following moderate
to severe brain trauma. There currently exist no approved treatments for this
medical problem therefore ensuring there are appropriate studies which can
evaluate the potential efficacy of a new treatment option is extremely
important. PENN will provide NeuroVive with important data regarding the
potential effect in this condition. These preclinical studies will complement
the ongoing CHIC study which is evaluating NeuroSTAT® in clinical practice.  The
preclinical research program will provide additional preclinical data for
NeuroSTAT® in the treatment of TBI to support the regulatory filings for the TBI
registration.

“We are very pleased to begin these preclinical studies in collaboration with
Drs. Susan Margulies and Todd Kilbaugh at the University of Pennsylvania and the
Children’s Hospital of Philadelphia who are experts in TBI experimental models.
The TBI research program is a priority for NeuroVive and we are putting extra
efforts to progress both the preclinical program as well as the CHIC trial to
ensure we understand the potential use of NeuroSTAT® in this serious medical
condition” said Magnus Hansson, Chief Medical Officer of NeuroVive.

“After extensive preparatory work, we have now begun the first phase of the TBI
program. It was important that we set up the first phase correctly as the
findings of this will be critical for the next two phases of the TBI program. We
have been working for several years to develop clinically relevant experimental
models of TBI, and believe that the testing of novel pharmaceutical treatments
in our models, such as NeuroSTAT®, will facilitate and improve the future
clinical development of TBI,” commented Dr. Susan S. Margulies, Professor in
Bioengineering and Neurosurgery at the University of Pennsylvania

About TBI
Traumatic brain injury (TBI) is brain damage that occurs after an external
trauma to the head, where nerve cells receive immediate damage. The injury
deteriorates for several days after the accident, often leading to a significant
impact on the overall injurious effect. TBI afflicts approximately 1.7 million
Americans annually with more than 52,000 associated deaths and 275,000
hospitalisations. [i] (http://file:///Q:/Neurovive/Pressreleaser/Skarpa/2016-04
-21%20-%20PENN%20TBI/2016-04-26%20
-%20NeuroVive%20starts%20preclinical%20TBI%20program%20in%20collaboration%20with
% 
20PENN.docx#_edn1) Both direct and indirect costs associated with TBI are
estimated at more than $60 billion with a high number of patients left with
moderate to severe disabilities requiring intensive care and support. It is
hoped that better treatments for TBI, such as NeuroSTAT®, will lead to increased
survival and greatly improved outcomes in terms of the ability of patients to
function normally following a severe TBI.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI), one candidate in
preclinical development and two drug discovery platforms. NeuroSTAT® has orphan
drug status in Europe and in the US for treatment of moderate to severe
traumatic brain injury and is currently being evaluated in a Phase II study.
CicloMulsion® is being evaluated in an on-going Phase II study, CiPRICS, in
acute kidney injury during major surgery. NeuroVive’s shares are listed on
Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, Tel: +46 (0)275 62 21 or ir@neurovive.com (ir@neurovive.com)

It is also possible to arrange an interview with NeuroVive’s CMO Magnus Hansson
at the above contacts.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on the 26 April 2016, at 8.30 CET.

----------------------------------------------------------------------

[i] (http://file:///Q:/Neurovive/Pressreleaser/Skarpa/2016-04-21%20
-%20PENN%20TBI/2016-04-26%20
-%20NeuroVive%20starts%20preclinical%20TBI%20program%20in%20collaboration%20with
% 
20PENN.docx#_ednref1) U.S. Centers for Disease Control and Prevention (CDC).
National Center for Injury Prevention and Control. Injury prevention and
control: traumatic brain injury. CDC website. Available at:
www.cdc.gov/traumaticbraininjury/statistics.html.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)